Clinical Trial Update: Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

A completed Phase 2, double-blind, placebo-controlled study evaluating oral dimebon (latrepirdine) in individuals with mild to moderate Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Dimebon (latrepirdine)

Snippet

Sponsor: Medivation, Inc. | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED